SCHEMBL21145656

SCHEMBL21145656

CCOc1cc(Br)cc(C=NNC(=O)c2ccccc2C)c1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
KLF5 Q13887 2/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
PIK3CG P48736 1/20 0.50
ALDH1A1 P00352 1/20 0.50
KDM4E B2RXH2 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
MITF O75030 1/20 0.49
GLA P06280 1/20 0.49
HTT P42858 1/20 0.49
MAPK1 P28482 1/20 0.49
RAB9A P51151 3/20 0.49
TDP1 Q9NUW8 2/20 0.48
NCOA3 Q9Y6Q9 1/20 0.47
PTK6 Q13882 1/20 0.47
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21145654 1.00 NPC1 (0.65) NPC1MEN1KMT2AKLF5L3MBTL1
SCHEMBL21145660 0.92 MEN1 (0.63) NPC1MEN1KMT2AKLF5L3MBTL1
SCHEMBL21145661 0.92 MEN1 (0.63) NPC1MEN1KMT2AKLF5L3MBTL1
SCHEMBL21145665 0.91 MEN1 (0.66) NPC1MEN1KMT2AKLF5L3MBTL1
SCHEMBL21145663 0.91 MEN1 (0.66) NPC1MEN1KMT2AKLF5L3MBTL1
SCHEMBL21145755 0.89 KMT2A (0.64) NPC1MEN1KMT2AKLF5L3MBTL1
SCHEMBL21145668 0.89 KMT2A (0.64) NPC1MEN1KMT2AKLF5L3MBTL1
SCHEMBL21145756 0.89 KMT2A (0.64) NPC1MEN1KMT2AKLF5L3MBTL1
SCHEMBL21145667 0.89 KMT2A (0.64) NPC1MEN1KMT2AKLF5L3MBTL1
SCHEMBL21168969 0.88 ATM (0.57) NPC1MEN1KMT2AKLF5L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515427-A2 N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE Qingdao Primedicine Pharmaceutical Co., Ltd (CN) 2019-07-31 EP claimed
US-11166924-B2 N-methyl-d-aspartate receptor allosteric modulators and methods for their use QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) 2021-11-09 US disclosed
US-20190216753-A1 N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190216753-A1 N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE GRIN2A, GRIN3A, GRIN1 NPC1 1570/4885MEN1 4774/4885KMT2A 585/4885
US-11166924-B2 N-methyl-d-aspartate receptor allosteric modulators and methods for their use GRIN2A, GRIN3A, GRIN1 NPC1 1570/4885MEN1 4774/4885KMT2A 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.